

1 **Dynamics of the SARS-CoV-2 epidemic in the earliest-affected areas in Italy:**
2 **Mass screening for SARS-CoV-2 serological positivity (SARS-2-SCREEN).**

3 Gabriele Pagani¹, Dario Bernacchia¹, Federico Conti¹, Andrea Giacomelli¹, Rossana
4 Rondanin⁶, Vittore Sclaris, Patrizia Boracchi⁴, Cecilia Eugenia Gandolfi² Silvana Castaldi^{2,3},
5 Elia Biganzoli^{4*}, Massimo Galli^{1*}.

6

7 *1: Department of Clinical and Biomedical Sciences (DIBIC) "L. Sacco", University of Milan, Italy*

8 *2: Post graduate School in Public Health Dept Biomedical Sciences for Health, University of Milan, Italy*

9 *3: Fondazione IRCCS Ca' Granda Ospedale Maggiore policlinico di Milano, Italy*

10 *4: Department of Clinical Sciences and Community Health & DSRC, University of Milan, Italy.*

11 *5: Institut Curie-PSL Research University, CNRS, Sorbonne Université, UMR3664, F-75005, Paris, France.*

12 *6: Medispa s.r.l.*

13

14 *Equally contributing Authors

15

16

17

18

19

20 **Corresponding Authors:**

21 Gabriele Pagani

22 gabriele.pagani@unimi.it

23 ASST FBF-Sacco, Infectious Diseases Dep., III Division

24 Luigi Sacco Hospital

25 Via G.B. Grassi 74, 20157

26 Milan, Italy

27

28 Cecilia Eugenia Gandolfi

29 cecilia.gandolfi@unimi.it

30 Department of Biomedical Sciences for Health

31 University of Milan

32 Via C. Pascal 36, 20133

33 Milan, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34

35 **ABSTRACT**

36 **Background** Several municipalities in the Lombardy Region have been affected by the SARS-
37 CoV-2 infection since the earliest stages of the epidemic. To date, 89442 confirmed cases have
38 been diagnosed in Lombardy, and mortality in several municipalities has already surpassed that
39 of the past decade. Currently, the true extent of the SARS-CoV-2 infection remains unknown
40 as several affected subjects may have been asymptomatic or have presented mild disease, thus
41 not resulting in the identified COVID-19 cases.

42 **Methods** This cross-sectional study aims to define the spread of infection within the population
43 by determining the seroprevalence of IgG antibodies directed against SARS-CoV-2 by rapid
44 immunochromatographic testing and subsequent confirmation by serology on venous blood by
45 liquid phase immunochemical testing, also allowing to compare the two methods. Testing will
46 be performed on adults and minors residing, domiciled or working in several municipalities of
47 the Lombardy Region, involved in the initial stages of the epidemic. The study will include
48 rapid finger-prick testing and venous sampling for antibodies against SARS-CoV-2, and
49 nasopharyngeal swabbing (NPS). Concurrent notification of test results will occur via the
50 regional healthcare information system (SISS).

51 **Discussion** This study was developed with the desire to understand the seroprevalence of
52 SARS-CoV-2 infection and the epidemiological transmission characteristics of this virus.
53 Understanding the spread and severity of the disease could help in the implementation of
54 effective infection surveillance containment and countermeasures facilitating the identification
55 of cases that have been exposed to the virus and the traceability of contacts.

56 **This study has been approved by the Ethics Committee of the University of Milan**
57 **(35/2020).**

58

59 **Keywords:** SARS-CoV-2, coronavirus, COVID-19, antibodies, prevalence, rapid test,
60 immunocromatographic test.

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84 **BACKGROUND**

85

86 Several municipalities of the Lombardy Region have been affected by the Severe Acute
87 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection since the earliest stages of the
88 epidemic. In fact, the first so called “red zone”, a quarantined area where all movements were
89 restricted, was established in the Lodi province (south-eastern Lombardy) on the 23rd of
90 February, following the first Coronavirus Induced Disease (COVID-19) hospitalization from
91 Codogno (LO).

92 To date, a total of 89442 SARS-CoV-2 cases have been confirmed in the Lombardy Region¹,
93 however the true extent of the SARS-CoV-2 infection remains unknown. In particular, the
94 number of infected subjects having presented minimal or no symptomatology has not been
95 precisely determined.

96 The World Health Organization (WHO) recognized the existence of a coronavirus responsible
97 for pneumonia in Wuhan, China on December 29th 2019². This virus, initially identified as n-
98 CoV-2019 (novel Coronavirus 2019), was subsequently referred to as SARS-CoV-2, and its
99 clinical manifestations known as Coronavirus Induced Disease 2019 (COVID-19). The
100 pandemic was declared on March 11th 2020³.

101 Currently, the WHO considers forwarding scientific knowledge on mass screening essential for
102 the battle against the spread of SARS-CoV-2, in order to allow better understanding and
103 planning of current and future containment policies.

104 All countries that have made extensive use of diagnostic testing on the whole population,
105 regardless of presence or absence of symptoms, have achieved a drastic drop in infection and
106 spread⁴.

107 To date, the only diagnostic tool to be officially recognized by the Italian Ministry of Health
108 for SARS-CoV-2 infection is the NPS, that uses real-time reverse transcription polymerase

109 chain reaction (rRT-PCR) to identify and amplify traces of the SARS-CoV-2 genome within a
110 patient's samples. This diagnostic method has several limits, including high costs, long
111 complete analysis times, and many false negatives (low diagnostic sensitivity).

112 Alongside the diagnostic aspect, the development of knowledge regarding disease spread and
113 prevalence in the population will become increasingly important in the near future. For this
114 reason, the development of research on seroprevalence with appropriate methods is of
115 fundamental importance.

116 This study was developed with the desire to understand the seroprevalence of SARS-CoV-2
117 infection and the epidemiological transmission characteristics of this virus in the earliest
118 affected areas in Italy. Understanding the spread and severity of the disease could help in the
119 implementation of effective infection surveillance containment and countermeasures
120 facilitating the identification of cases that have been exposed to the virus and the traceability of
121 contacts.

122

123 **METHODS & DESIGN**

124 The primary objective of this cross-sectional study is to determine the spread of infection within
125 the population by determining the seroprevalence of IgG antibodies directed against SARS-
126 CoV-2 by rapid immunochromatographic testing and subsequent confirmation by serology on
127 venous blood by liquid phase immunochemical testing.

128 Secondary objectives include comparing IgG and IgM antibody positivity obtained by rapid
129 testing via direct viral research to serological data obtained by the immunochemical method.

130 We also aim to establish a database for future prospective projects eg. serial antibody titer
131 assessed over time, possibly expanding the study to several municipalities particularly affected
132 by the SARS-CoV-2 epidemic around the Lombardy region. This may help localize and isolate
133 possible current and future outbreaks.

134 For the municipalities included in first so-called “red zone”, thus more severely hit, we
135 hypothesize a seroprevalence of IgG antibodies directed against SARS-CoV-2 between 30%
136 and 50%, due to probable unrestricted viral circulation in the days or weeks before the first
137 hospitalized case. For the other, less severely affected, municipalities we estimate a prevalence
138 between 10 and 30%.

139 According to current regional legislation (DGR n. XI/3114 and DGR n. XI/3131) during the
140 second phase of the epidemic, NPS will be performed in all symptomatic individuals, flagged
141 as “suspect COVID-19 cases” by their family doctor, and in all traced contacts prior to
142 readmission in society. Although rRT-PCR on NPS is the current gold standard diagnostic test
143 for SARS-CoV-2, diagnostic accuracy depends on several pre-analytical and analytical
144 variables, and many patients can be asymptomatic (thus currently will not receive testing in the
145 Lombardy region). The measurement of specific COVID-19 antibodies could serve as an
146 additional tool for disease detection and management, playing a potential key role in
147 surveillance and screening. The latter may be even more advantageous if implemented in the
148 form of rapid finger-prick testing. In fact, as mentioned above, one of our secondary objectives
149 is the comparison of IgG and IgM antibody positivity obtained by rapid testing, to serological
150 data obtained by the immunochemical method. We hypothesize that antibody detection by rapid
151 finger-prick testing will be non-inferior to detection by venous sampling.

152 Testing will be performed at specific locations in the various municipalities, equipped with the
153 following rooms:

- 154 • A waiting room of suitable size to allow the simultaneous presence of 8-10 evenly
155 spaced (at least 1.8 m apart) individuals equipped with suitable PPE (surgical masks).
- 156 • A room for collection of personal data and for carrying out rapid tests.
- 157 • A room for the execution of venous blood samples.
- 158 • A room for carrying out NPS.

159 • A room for the dressing and undressing of healthcare workers.

160 • A storage room with refrigerator.

161

162 **Inclusion and exclusion criteria**

163 All following subjects may be included in the study:

164 1. The entire adult population living in the municipality, including residential care
165 facilities.

166 2. All individuals over 18 who were present in the municipality on a daily basis for work
167 reasons during the epidemic eg. law enforcement officers, traders, workers in local
168 companies etc.

169 3. All minors residing and/or domiciled in the municipality, upon explicit
170 parental/guardian request.

171 An absolute exclusion criterion is represented by being quarantined. However, data regarding
172 quarantine will be taken into account for defining the dynamics of the epidemic.

173

174 **Population follow-up and counseling**

175 1. Individuals with **negative** results to rapid testing who do not present symptoms
176 suggestive for acute infection will be sent home, after counseling on appropriate
177 behaviors aimed at avoiding infection.

178 2. Individuals with **negative** results to rapid testing who, however, present symptoms
179 suggestive for acute infection will be evaluated by medical personnel to determine the
180 need for further investigations (imaging or ER access) and quarantined, at home or in a
181 different location if home is deemed unsuitable, pending swab results. These individuals
182 will receive extensive counseling on best-practices during the quarantine period.

- 183 3. Individuals with **positive** results to IgM rapid testing, regardless of IgG results, will be
184 quarantined at home, or in a different location if home is deemed unsuitable, pending
185 swab results. If swab results are also positive, quarantine will be confirmed and
186 extended and counseling on best-practices during the quarantine period will be
187 provided.
- 188 4. Individuals with **positive** results to IgG rapid testing only will be sent home, without
189 need for fiduciary quarantine.
- 190 5. Quarantined individuals will be provided with pulse oximeter, surgical masks and
191 extensive counseling on best-practices during the quarantine period.
- 192 6. All **swab positive** individuals, regardless of rapid test results, will be notified to local
193 health authorities using a specific infectious disease digital notification platform for the
194 Lombardy Region. The swab positive individual will thus be quarantined, and follow-
195 up will be carried out by the local health authorities, as indicated in current regional
196 protocols.

197

198 **Results reporting**

199 Rapid test results will be communicated in real time and a full report comprising collected
200 anamnestic and epidemiological data, and rapid test results will be emailed or printed, according
201 to patient preference.

202 NPS results will be communicated as follows:

- 203 - In case of a negative result, attending medical personnel will call the patient directly.
- 204 - In case of a positive result, attending medical personnel will call the patient's family
205 doctor, who will then notify the local health authorities via the regional infectious
206 disease digital notification platform, and communicate the positive result to the patient.

207

208 **Sample management**

- 209 1. Rapid tests will be analyzed by assigned staff within the timeframe suggested by the
210 manufacturer and will then be suitably disposed of by the same staff (biohazardous
211 waste).
- 212 2. Venous blood samples will be stored on site, refrigerated at +4°C, and transported to
213 the lab for analysis, daily.
- 214 3. Swabs will be stored on site, refrigerated at +4°C, and transported to the lab for analysis,
215 daily (or within 48 hours during the weekend). NPSs are placed in a triple container
216 during transportation: the collection tube is placed in a conical tube (“falcon” type tube),
217 and then in a spill proof box.

218

219 **Sampling plan and determination of sample size**

220 For the purposes of the primary objective of the study, random sampling will be carried out
221 from the municipal registry list, stratifying by gender and conventional age classes (0-19; 20-
222 39; 40-59; >=60). At present, geographical stratification does not seem necessary given the
223 homogenous distribution of cases identified to date. Confirmed cases that have already been
224 identified in the municipality must be included in the study sample with the same probability
225 as other subjects. In fact, the rapid test and venous sample seroprevalence results on previously
226 confirmed cases will provide further data useful for comparison.

227 A sample size of 355 subjects from a population of 4616 individuals provides a bilateral 95%
228 confidence interval with an accuracy (half-amplitude) of 0.05 when actual prevalence is close
229 to 0.5%. In case of higher or lower prevalence, the sample size decreases to 302 subjects in case
230 of prevalence equaling 0.3, very close to current estimates, and to 234 subjects in case of a more
231 skeptical prevalence hypothesis of 0.8. Considering the largest population sample combined to
232 a possible 20% drop-out, sample size increases to 444 subjects.

233 Assuming an infinite population^{7,8}, sample size would be determined at 402 subjects, to be
234 increased to 503 subjects considering 20% drop-out. Thus, a sample size of around 500 subjects
235 would seem reasonable for the main study objective.

236 Regarding the secondary objective, relating to sensitivity and specificity of the rapid test
237 compared to the gold-standard on venous blood samples, the sample size required for a bilateral
238 95% confidence interval with a maximum amplitude of 0.1, is 527 subjects for sensitivity and
239 438 subjects for specificity, assuming a prevalence of 0.3 with optimal sensitivity and
240 specificity equal to 0.9. Thus, in order for both confidence intervals to have a maximum
241 amplitude of 0.1, the largest of the two sample sizes (527 subjects) must be chosen⁹. Also,
242 sample size should be further increased to 659 subjects to allow for 20% drop-out.

243 Accordingly, in case of hypothesized sensitivity and specificity values equal to 0.8, the sample
244 size should be increased to 880 subjects, and to 1100 subjects to include 20% drop-out.

245 However, in an optimal situation, the sample size required for the secondary objective appears
246 compatible with that needed for the primary objective. In fact, a study that could effectively
247 recruit at least 500 people would continue to offer expected amplitudes of confidence intervals
248 up to 0.144 for sensitivity and <0.1 for specificity, even in conditions of lower diagnostic
249 performance, always hypothesizing a prevalence of 0.3.

250 Sample size calculations were carried out using PASS v. 16.0.3 validated software.

251

252 **DISCUSSION**

253 **Location and testing procedures**

254 Testing will be performed at various locations in the selected municipalities, equipped with the
255 following rooms:

- 256 • A waiting room of suitable size to allow the simultaneous presence of 8-10 evenly
257 spaced (at least 1.8 m apart) individuals equipped with suitable PPE (surgical masks).

258 • A room for collection of personal data and performing rapid tests.

259 • A room for the execution of venous blood samples.

260 • A room for carrying out NPS.

261 • A room for the dressing and undressing of healthcare workers.

262 • A storage room with refrigerator.

263 Separate paths will be defined for the entrance and exit of tested subjects, particularly to prevent

264 loitering between individuals waiting to be tested and those already tested, as well as to prevent

265 large gatherings in confined spaces like corridors, making social distancing impracticable.

266

267 Subjects are tested as follows:

268 1. Assembly of up to 10 people every 30 minutes to be examined according to geographical

269 location. Participation in the study is voluntary. Those called upon must be equipped

270 with a correctly worn surgical mask. Security personnel will be assigned to ensure

271 correct use of PPE and compliance with safety distance.

272 2. Acquisition of informed consent.

273 3. Rapid testing for antibodies against SARS-CoV-2 in all individuals in the assembled

274 group.

275 4. Anamnestic and personal data collection on a local network electronic database and

276 printing of labels for sample identification.

277 5. Venous blood sampling in all those resulting positive to the rapid test and, at random,

278 in a proportion of negative subjects, still to be determined.

279 6. Swabbing of all individuals resulting positive to the rapid test, all people with recent

280 history of symptoms compatible with COVID-19, and in a proportion of negative

281 subjects, yet to be determined, chosen at random.

282 Given that examining the largest number of people in the shortest time possible is of paramount
283 importance in a cross-sectional study, we decided to perform rapid testing as the first procedure,
284 and to gather epidemiological and anamnestic data while waiting for the appropriate reading
285 time (10 to 20 minutes). This will enable us to perform between 200 and 250 rapid tests per
286 day.

287

288 **Personnel protection measures**

289 Seeing as the SARS-CoV-2 epidemic is still active in the Lombardy region, participant and
290 personnel safety will be a main concern. Personal protective equipment (PPE) and sanitization
291 of all rooms and equipment will be guaranteed for the all duration of the study.

292 All patients must be equipped with a correctly worn surgical mask and disposable gloves.

293 PPE will be provided according to personnel role, as follows:

- 294 1. Surgical mask and disposable gown for personnel assigned to anamnestic, personal data,
295 and rapid test collection
- 296 2. FFP2 or equivalent filtered mask, surgical cap, visor, gloves and waterproof disposable
297 gown for personnel assigned to NPS collection and venous sample collection.

298 Moreover, we decided to position a plexiglass barrier with a specifically-designed hole through
299 which the rapid test is performed. This guarantees additional safety for personnel assigned to
300 rapid testing and data collection, without the discomfort of wearing PPEs. The same barrier was
301 proposed to the nurses assigned to venous blood sampling, but was not implemented based on
302 previous negative experiences with this method of blood collection through the plexiglass
303 barrier.

304 Rooms and surfaces will be sanitized three times a day using 0.1-0.5% sodium hypochlorite
305 solution for large surfaces eg. floors, walls, chairs; and 62-71% alcohol for small surfaces
306 (whenever there is biological contamination) and remaining instrumentation.

307 Sanitization will be carried out with disposable cloths or paper towels, to be suitably eliminated
308 (biohazardous waste).

309 Sanitization of any medical devices (sphygmomanometer, pulse oximeter, etc.) will be carried
310 out between each use.

311

312 **Data management**

313 Study data will initially be stored on a certified database of the i-Care platform, provided by
314 MEDISPA. Subsequently, an original database will be created, in collaboration with the
315 University of Milan Data Science Research Center, for data processing and analysis, according
316 to i-Care database data protection requirements, from which data transfer will take place.

317 Patient data will be traceable to a completely anonymous identification code (no data from
318 which patient identity could be derived will be recorded), thus only the doctor assigned to
319 patient data collection and, if required, subjects authorized by national privacy regulations will
320 be able to trace data back to the specific patient via the abovementioned identification code. In
321 any case, these subjects are bound by confidentiality according to current legislation. Patient
322 data will be made public only via scientific publications or conferences, and only in anonymous
323 aggregate form, always respecting current privacy laws (including but not limited to, “*legge*
324 *privacy*”, 18/05/2018, n. 51 Legislative Decree; and the EU (GDPR) 2016/679¹⁰).

325 The protection of individuals will also be guaranteed according to the Oviedo Convention¹¹ and
326 the Declaration of Helsinki regarding ethical principles for medical research involving human
327 subjects¹², adopted by the World Medical Association in 1964.

328

329

330

331

332 **LIST OF ABBREVIATIONS**

333 **SARS-CoV-2** severe acute respiratory syndrome coronavirus 2

334 **COVID-19** COronaVirus Induced Disease 2019

335 **rRT-PCR** real-time reverse transcription polymerase chain reaction

336 **NPS** nasopharyngeal swab

337 **SISS** Sistema Informativo SocioSanitario (regional healthcare information system)

338 **WHO** World Health Organization

339 **PPE** personal protective equipment

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357 **BIBLIOGRAPHY**

358

359 1. Total COVID-19 cases by province. In: COVID-19 in Italy – Monitoring by the Civil
360 Protection Department. 2020.

361 [http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce47](http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1)
362 [8eaac82fe38d4138b1](http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1) Accessed 4 June 2020.

363 2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
364 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
365 descriptive study. *The Lancet*. 2020;395:507–13

366 3. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11
367 March 2020. [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
368 [remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020) Accessed 14 Apr 2020.

369 4. WHO | Coronavirus disease (COVID-2019) R&D. WHO. World Health Organization.
370 2020. <http://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/>
371 Accessed 27 Mar 2020.

372 5. COVID-19 Report by ISS n. 11/2020 – Reccomendations for the correct sampling,
373 conservation and analysis of COVID-19 oro/nasopharyngeal swabs. 2020.
374 <http://www.iss.it/documents/20126/0/Rapporto+ISS+COVID-> Accessed 14 Apr 2020.

375 6. Machin D, Campbell M, Tan SB, and Tan SH. *Sample Size Tables for Clinical*
376 *Studies*. 3rd ed. Chichester, UK: Wiley-Blackwell; 2009.

377 7. Fleiss JL, Levin B, Paik MC. *Statistical Methods for Rates and Proportions*. 3rd ed.
378 New York: John Wiley & Sons; 2003.

379 8. Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion:
380 Comparison of Seven Methods. In: *Statistics in Medicine*; 1998. p. 857-872.

- 381 9. Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical
382 informatics. *Journal of Biomedical Informatics*. 2014;48:193-204.
- 383 10. Regulation (EU) 2016/679 of the European Parliament and of the council of 27 April
384 2016 on the protection of natural persons with regard to the processing of personal
385 data and on the free movement of such data, and repealing Directive 95/46/EC
386 (General Data Protection Regulation) . In: EuroLex – Access to European Union law.
387 <https://eur-lex.europa.eu/eli/reg/2016/679/oj> Accessed 7 May 2020.
- 388 11. Convention for the protection of Human Rights and Dignity of the Human Being with
389 regard to the Application of Biology and Medicine: Convention on Human Rights and
390 Biomedicine. In Council of Europe Treaty Office. 1997.
391 <https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/164> Accessed on
392 8 May 2020.
- 393 12. Declaration of Helsinki regarding ethical principles for medical research involving
394 human subjects. In World Medical Association. [https://www.wma.net/policies-
395 post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-
396 human-subjects/](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) Accessed 7 May 2020.
- 397
398
399
400
401
402
403
404
405

406 **DECLARATIONS**

407 **Ethics approval and consent to participate**

408 The study have been performed in accordance with the Declaration of Helsinki and was
409 approved by the Ethics Committee of the University of Milan on the 21st of April 2020
410 (reference number 35/2020). Informed consent to participate in the study will be obtained in
411 written form from all participants, or their parent or legal guardian in case of minors.

412

413 **Consent for publication**

414 Not applicable.

415

416 **Availability of data and materials**

417 The datasets used and analysed during the current study are available from the corresponding
418 author on reasonable request.

419

420 **Competing interests**

421 The authors declare that they have no competing interests.

422

423 **Funding**

424 This study will be carried out with the non-conditioning contribution of CISOM, Fondazione
425 Rava, Armani C/O Unimi e Mediolanum C/O Fbf/Sacco.

426 Vittoire Scolari received support from the LabEx DEEP (ANR-11-LABX-0044, ANR-10-
427 IDEX-0001-02)

428

429

430

431

432 **Authors' contributions**

433 MG, GP, DB, AG and FC contributed to the conception and design of the protocol and revised

434 the manuscript;

435 EB and PB contributed to the design of the protocol, the acquisition, analysis and interpretation

436 of data, and revision of the work;

437 RR and VS contributed to the acquisition, analysis and interpretation of data;

438 CEG and SC drafted and substantially revised the work.

439 All authors declare to approve the submitted version and agree to be personally accountable for

440 their contributions.

441

442 **Acknowledgements**

443 The authors would like to acknowledge the substantial contribution provided by Medispa

444 s.r.l., which contributed to the protocol by providing expertise, personnel and the informatic

445 platform.